Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy
2009
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KIT AY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
2009
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
2006
Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1
2008
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
2009
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
2006
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
2006
Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
2009
A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours
2011
Gastrointestinal stromal tumour
2007
The role of KIT in the management of patients with gastrointestinal stromal tumors
2007
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
2014
Beyond Imatinib: Second Generation c-KIT Inhibitors for the Management of Gastrointestinal Stromal Tumors
2006
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
2014
Epigenetics in cancer
2009 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
2008
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
2008
Gastrointestinal stromal tumor: 5 years later
2005
Translation of new cancer treatments from pet dogs to humans
2008 Standout
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
2008
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
2006
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
KIT Mutations in GIST
2007
Point mutations of protein kinases and individualised cancer therapy
2006
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
2008
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
The cancer genome
2009 StandoutNature
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
2006
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680
2006
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
2009
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
2008
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
2015 Standout
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
2006
Natural product and natural product derived drugs in clinical trials
2014 Standout
Works of Nadja Thomas being referenced
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
2005
Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate
2006